How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
Exact Sciences has unveiled new findings from a case-control study demonstrating the potential of its advanced multi-biomarker class approach to…
Fresh off positive data presented at the Clinical Trials on Alzheimer’s Disease 2024 (CTAD) conference earlier this month, Sinaptica’s CEO,…
US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord stimulation…
Paloma Health has raised £2m ($2.56m) to roll-out its autism assessments for children in the UK National Health Service (NHS). …
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a…
Cofactor Genomics has showcased positive data highlighting that its clinical biomarker assay OncoPrism-HNSCC could guide doctors in choosing more effective…
Patients at the University of Kansas Health System in the US have been successfully treated with Stereotaxis’ endovascular robotic system.…
Johnson & Johnson’s (J&J) Shockwave Medical unit has reported that its Javelin peripheral intravascular lithotripsy (IVL) catheter system successfully met…
Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience…